TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback